恩華葯業財務指標

A. 恩華葯業的財務分析

規模增長指標
恩華葯業過去三年平均銷售增長率為14.31%,在所有上市公司排名（984/1710），在其所在的葯品零售行業排名為11/16，外延式增長合理
EPS成長性
恩華葯業過去EPS增長率為9.35%，在所有上市公司排名（836/1710），在其所在的葯品零售行業排名為14/16，公司成長性較差
盈利能力指標
恩華葯業過去三年平均盈利能力增長率為36.86%，在所有上市公司排名（630/1710），在所在的葯品零售行業排名為 （10/16）。盈利能力合理
EPS穩定性
恩華葯業過去EPS穩定性在所有上市公司排名（1/1710），在其所在的葯品零售行業排名為1/16 。公司經營穩定較好

B. 幫忙翻譯下面中文摘要，萬分感謝~~~~~~~~~~~~~

The United States of AmericaDun & Bradstreet Corporationin early twenty-first Centuryhad onChineseenterprise creditanddebt recoverywere investigated,results showed that 67%enterprises are notindependent of thecredit managementdepartment.Furthermore,according to the Ministry of commercedata display,Chineseenterprisesevery year because oflack of creditlead to directand indirecteconomic losses of up to600000000000 yuan.With the development of market economy,enterprise creditsystem in order tograallybecome an importantpart of the social credit system,its importance is increasinglyobvious.China'spharmaceuticalenterprises in seventy or eightypercentare usingcreditmeanscredit,bad debts,accounts receivable recoveryperiodof enterprise development,high cost ofcreditmanagementproblem has beenplaced in front ofeachmedicine enterprise.In the face ofthis phenomenon,the establishment of acomplete and effectivecreditmanagement system is essential.
This paper uses the method ofcombining theory and case studies,through the research and analysisof credit managementtheory,combined with theEn-hua medicinein the pharmaceutical instry,themarket environmentand ,En-hua medicineto design a set ofenterprise development in line with therequirements of themanagement system.The articleis composed of five parts:
The first chapter is the introction,mainlythe research background significance,theframeworkand the domestic and foreignliterature reviewprocess.Inthe literature review at home and abroad,not onlyintroced the domestic and foreigntheory isfamous,and fortheuse ofseveral of the mostwidelycredit managementmodelfor comparative analysis.
The second chapterreviewsthe credit management systemof enterprises,a detailed analysis of therelated conceptsof credit management,and explains that theDSOevaluation indexof the implementation ofenterprise creditmanagementand creditpolicy.
The third chapterour country enterprise management statusof credit,through in-depth analysis ofthe current creditmanagement of the enterprises of our country,find out thedifficulties in implementationof enterprise credit managementand the existing problems.
The fourth chapter is the analysis ofEnhua system diagnosis,discussingEnhua pharmaceuticalBeijingand operatingcharacteristic,carries on the analysis to theinternalmanagement system,En-hua medicineis now the village,find out the advantages and disadvantages,and then introce thedesign ideaof the newsystem.
Design of the fifth chapterEnhua pharmaceuticalnewcredit management systemand perfect,to do a detailed description ofthecredit management departmentand the establishment ofcreditmanagement of all aspects oftheoperation,and to .
The purpose of this paper isan applicablemanagement systemdesign oftherapid developmentasEnhua ,combined with thefinancial managementwith our currentcreditsituation,hope to havesome referencefor such enterprises.

C. 目前深圳股市最具投資潛力的股票有哪些

其實股票原本就不需要那麼多地方的戶頭,做得好,有個深圳的就夠了,做不好,即便A,H,S,B都有也照樣虧損.人的精力有限,研究5隻股票明白了,也可以滾雪球一樣越做越大,不要貪多是對的,推薦股票如下:

A 登海種業002041：農業龍頭概念，投資組合中必不可少的保值、增值股，拉動內需目前尚未在農村發展起來，原因就是我國農業欠發達狀態仍未改變，未來的幾十年裡，農業都有穩步前進的動力。登海種業、北大荒、新農開發是我國的良種作物、大規模耕地、棉花的三大龍頭，考慮到未來發展前景，登海種業比起後者更占優勢。並且位於東部沿海地區（山東）對於業績開展、產品銷售都有不可比擬的優勢。該股一直維持強勢走勢，表達了市場對其良好預期
B 張裕A 002869：消費板塊里，酒水是上市股票中的大類。白酒市場茅台一家獨大，未來價值必然看好。但是這一點大家都抱有信心，因此二級市場上該股不會有什麼大幅起落，一定是抗跌、難炒，所以反而不會有太好機會。這個時候選取張裕A其實是出奇制勝的做法。我國葡萄酒市場剛剛開展，並且隨著人口素質提高，葡萄酒的健康概念必將深入人心，從而改變國內酒水消費市場的格局，而張裕是我國葡萄酒的絕對第一品牌，其領域優勢猶勝茅台。今年張裕收回了解百衲的高級葡萄酒專利品牌，未來的業績暴增可期
C 萬科A 000002 作為國內地產龍頭，目前的價格和市盈率顯得極為低估，地產畢竟是我國的朝陽行業，經歷了高速發展以後略有停滯甚至倒退都是正常的，目前市場對於地產的預期和評價都很不好，所以股價會難得的便宜。今後地產的發展是沒有任何人能夠否定的 .一句話，長線的話持有地產一定賺錢，並且一定賺大錢